GlassScriptPhysician profile
Brian K Few
NPI 1255390704
$4,289.43
in general payments reported to CMS, 2019-2025
20 companies · $451 in 2025
The $451 reported for 2025 was more than what 90% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $583 · 2021: $704 · 2022: $682 · 2023: $575 · 2024: $898 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $1,450.85 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $597.01 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $559.56 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $408.71 | 2021-2025 | Azstarys |
| Pfizer INC. | $198.94 | 2019-2025 | |
| Neos Therapeutics, LP | $186.67 | 2019-2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Cranial Technologies, INC | $178.57 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $157.97 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $109.07 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $97.95 | 2024-2025 | |
| Adlon Therapeutics L.P. | $80.83 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.50 | 2019-2021 | |
| Genentech USA, INC. | $63.86 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $27.48 | 2022-2024 | Gardasil, Gardasil 9, Vaxelis |
| Noven Therapeutics, LLC | $22.36 | 2024 | Xelstrym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $17.57 | 2023 | Immunocap |
| Seqirus USA INC | $15.73 | 2024 | Flucelvax |
| Vertical Pharmaceuticals, LLC | $14.18 | 2025 | Relexxii |
| Mission Pharmacal Company | $12.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Few listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.